Isis Pharmaceuticals, Inc.
ISIS announced today that it has earned a $6 million payment from
AstraZeneca related to continuation of the research collaboration between Isis
and AstraZeneca to discover and develop novel antisense therapeutics to treat
cancer. In addition to the research collaboration, which includes three
cancer targets, Isis and AstraZeneca are developing two antisense drugs,
ISIS-AR[Rx] and ISIS-STAT3[Rx], discovered by Isis and licensed to AstraZeneca
for the treatment of cancer.
In December 2012, Isis entered into a collaboration with AstraZeneca to
discover and develop antisense drugs to treat cancer. The collaboration
combines AstraZeneca's experience and expertise in developing anti-cancer
agents with Isis' antisense technology platform to broaden Isis' cancer
franchise. With the $6 million payment, Isis has earned $41 million in
upfront and milestone payments from AstraZeneca and is eligible to earn
additional milestone payments as the collaboration progresses and royalties on
sales of drugs resulting from the collaboration.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in